<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01054404</url>
  </required_header>
  <id_info>
    <org_study_id>STU00016126</org_study_id>
    <nct_id>NCT01054404</nct_id>
  </id_info>
  <brief_title>Furosemide vs Placebo for Brain Relaxation</brief_title>
  <official_title>The Effect of Furosemide Versus Placebo on Brain Relaxation and Incidence of Significant Intravascular Volume Depletion in Human Subjects Receiving Mannitol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Increased brain bulk may be problematic during brain surgery for tumors because it may limit
      surgical exposure and access to the surgical site. Mannitol, an osmotic diuretic, is commonly
      given to alleviate brain bulk, and sometimes furosemide in a small dose is added if mannitol
      alone is insufficient. It is unclear if adding this furosemide truly helps to diminish brain
      bulk, and it is possible that furosemide may cause too much diuresis, leading to dehydration
      and its side effects (e.g., low blood pressure). Our purpose is to investigate what the
      effects of furosemide are in the setting of brain surgery for tumors, specifically with
      regards to decreasing brain bulk and/or causing dehydration.

      Study Hypothesis: The addition of furosemide to mannitol will result in improved brain
      relaxation in human subjects undergoing craniotomy for brain tumor resection than that seen
      with mannitol alone. However, the combination of mannitol and furosemide will also lead to
      more significant intravascular volume depletion than that seen with mannitol alone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rating of brain relaxation will be on a 4-point scale:

      0 = brain very relaxed under dura, acceptable

        1. = brain adequately relaxed under dura, acceptable

        2. = brain slightly tense under dura, acceptable

        3. = brain very tense under bulging dura, unacceptable
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Concern for volume depletion and electrolyte abnormalities in furosemide arm.
  </why_stopped>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acceptable vs. Unacceptable Brain Relaxation at Dural Opening</measure>
    <time_frame>just prior to dural opening for each subject</time_frame>
    <description>Rating of brain relaxation will be on a 4-point scale:
0 = brain very relaxed under dura, acceptable
= brain adequately relaxed under dura, acceptable
= brain slightly tense under dura, acceptable
= brain very tense under bulging dura, unacceptable</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Brain Swelling</condition>
  <condition>Brain Edema</condition>
  <condition>Dehydration</condition>
  <arm_group>
    <arm_group_label>Furosemide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Furosemide 0.3 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Up to 5 mL saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Furosemide</intervention_name>
    <description>Furosemide 0.3 mg/kg</description>
    <arm_group_label>Furosemide</arm_group_label>
    <other_name>Lasix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo (up to 5mL)</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Inclusion criteria include:

               -  ASA PS I-III

               -  Age 18 or older

               -  Presenting for elective resection of primary or metastatic supratentorial brain
                  tumor(s)

        Exclusion Criteria:

          -  â€¢ ASA PS IV or V

               -  Age less than 18

               -  Emergency surgery due to severely elevated ICP/impending brainstem herniation

               -  Concurrent use of diuretics for any indication

               -  Infratentorial/posterior fossa/cerebellar tumor resection

               -  Moderate/severe cardiac disease with limitation in contractility as measured by
                  preoperative echocardiogram (EF &lt; 30%)

               -  Severe pulmonary hypertension as measured and/or observed by preoperative studies

               -  Preoperative use of steroids (within 6 months, including those on standing doses)

               -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John F Bebawy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dhanesh K Gupta, MD</last_name>
    <role>Study Director</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Thenuwara K, Todd MM, Brian JE Jr. Effect of mannitol and furosemide on plasma osmolality and brain water. Anesthesiology. 2002 Feb;96(2):416-21.</citation>
    <PMID>11818776</PMID>
  </reference>
  <reference>
    <citation>Todd MM, Cutkomp J, Brian JE. Influence of mannitol and furosemide, alone and in combination, on brain water content after fluid percussion injury. Anesthesiology. 2006 Dec;105(6):1176-81.</citation>
    <PMID>17122580</PMID>
  </reference>
  <reference>
    <citation>Rudehill A, Lagerkranser M, Lindquist C, Gordon E. Effects of mannitol on blood volume and central hemodynamics in patients undergoing cerebral aneurysm surgery. Anesth Analg. 1983 Oct;62(10):875-80.</citation>
    <PMID>6412595</PMID>
  </reference>
  <reference>
    <citation>Todd MM, Warner DS, Sokoll MD, Maktabi MA, Hindman BJ, Scamman FL, Kirschner J. A prospective, comparative trial of three anesthetics for elective supratentorial craniotomy. Propofol/fentanyl, isoflurane/nitrous oxide, and fentanyl/nitrous oxide. Anesthesiology. 1993 Jun;78(6):1005-20.</citation>
    <PMID>8512094</PMID>
  </reference>
  <reference>
    <citation>Rozet I, Tontisirin N, Muangman S, Vavilala MS, Souter MJ, Lee LA, Kincaid MS, Britz GW, Lam AM. Effect of equiosmolar solutions of mannitol versus hypertonic saline on intraoperative brain relaxation and electrolyte balance. Anesthesiology. 2007 Nov;107(5):697-704.</citation>
    <PMID>18073543</PMID>
  </reference>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 20, 2010</study_first_submitted>
  <study_first_submitted_qc>January 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 22, 2010</study_first_posted>
  <results_first_submitted>May 8, 2013</results_first_submitted>
  <results_first_submitted_qc>June 27, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 2, 2013</results_first_posted>
  <last_update_submitted>June 27, 2013</last_update_submitted>
  <last_update_submitted_qc>June 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 2, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>John Bebawy</investigator_full_name>
    <investigator_title>Assistant Professor of Anesthesiology &amp; Neurological Surgery</investigator_title>
  </responsible_party>
  <keyword>Brain Swelling</keyword>
  <keyword>Brain Edema</keyword>
  <keyword>Dehydration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dehydration</mesh_term>
    <mesh_term>Brain Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Furosemide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>23 patients enrolled sequentially, no dropouts</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Furosemide</title>
          <description>Furosemide : Furosemide 0.3 mg/kg</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo : Placebo (up to 5mL)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Furosemide</title>
          <description>Furosemide : Furosemide 0.3 mg/kg</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo : Placebo (up to 5mL)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="23"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51" spread="16.6"/>
                    <measurement group_id="B2" value="52.1" spread="15.6"/>
                    <measurement group_id="B3" value="51.6" spread="15.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Acceptable vs. Unacceptable Brain Relaxation at Dural Opening</title>
        <description>Rating of brain relaxation will be on a 4-point scale:
0 = brain very relaxed under dura, acceptable
= brain adequately relaxed under dura, acceptable
= brain slightly tense under dura, acceptable
= brain very tense under bulging dura, unacceptable</description>
        <time_frame>just prior to dural opening for each subject</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Furosemide</title>
            <description>Furosemide : Furosemide 0.3 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo : Placebo (up to 5mL)</description>
          </group>
        </group_list>
        <measure>
          <title>Acceptable vs. Unacceptable Brain Relaxation at Dural Opening</title>
          <description>Rating of brain relaxation will be on a 4-point scale:
0 = brain very relaxed under dura, acceptable
= brain adequately relaxed under dura, acceptable
= brain slightly tense under dura, acceptable
= brain very tense under bulging dura, unacceptable</description>
          <units>units on a scale 0-3</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread=".17"/>
                    <measurement group_id="O2" value="1.3" spread=".13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Furosemide</title>
          <description>Furosemide : Furosemide 0.3 mg/kg</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo : Placebo (up to 5mL)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Recruitment was stopped at 23 subjects because of concern that the administration of furosemide was producing such a large diuresis that clinically significant and potentially unsafe hypovolemia and electrolyte abnormalities were developing.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. John F. Bebawy, Assistant Professor of Anesthesiology &amp; Neurological Surgery</name_or_title>
      <organization>Northwestern University</organization>
      <phone>312-695-0061</phone>
      <email>j-bebawy@northwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

